Compare NUS & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUS | TENX |
|---|---|---|
| Founded | 1984 | 1967 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 266.5M | 317.8M |
| IPO Year | 1996 | 2001 |
| Metric | NUS | TENX |
|---|---|---|
| Price | $4.83 | $1.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $29.67 |
| AVG Volume (30 Days) | 538.1K | ★ 6.2M |
| Earning Date | 05-07-2026 | 05-15-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ 207.80 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,176,718,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.14 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 48.98 | N/A |
| 52 Week Low | $4.49 | $1.31 |
| 52 Week High | $14.62 | $19.40 |
| Indicator | NUS | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 38.87 | 18.20 |
| Support Level | N/A | N/A |
| Resistance Level | $5.51 | $16.39 |
| Average True Range (ATR) | 0.23 | 0.88 |
| MACD | -0.04 | -1.52 |
| Stochastic Oscillator | 33.66 | 3.42 |
Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.
Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.